Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Life Threatening Diseases Clinical Trial

Official title: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Status Completed

Clinical Trial Summary

Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Life Threatening Diseases
• Rare Diseases

• NCT number: NCT00154388
• Study type: Interventional
• Source: Novartis
• Status: Completed
• Phase: Phase 2
• Start date: February 2001
• Completion date: January 2007